These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

807 related articles for article (PubMed ID: 8263772)

  • 1. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of dopaminergic and GABAergic neurotransmission: impact of 6-hydroxydopamine lesions into the substantia nigra of rats.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1995 Oct; 275(1):237-44. PubMed ID: 7562556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
    Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
    Sonsalla PK; Manzino L; Heikkila RE
    J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
    Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
    Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
    Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
    J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interhemispheric modulation of dopamine receptor interactions in unilateral 6-OHDA rodent model.
    Lawler CP; Gilmore JH; Watts VJ; Walker QD; Southerland SB; Cook LL; Mathis CA; Mailman RB
    Synapse; 1995 Dec; 21(4):299-311. PubMed ID: 8869160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 6-OHDA-induced hemiparkinsonism and chronic L-DOPA treatment increase dopamine D1-stimulated [(3)H]-GABA release and [(3)H]-cAMP production in substantia nigra pars reticulata of the rat.
    Rangel-Barajas C; Silva I; García-Ramírez M; Sánchez-Lemus E; Floran L; Aceves J; Erlij D; Florán B
    Neuropharmacology; 2008 Oct; 55(5):704-11. PubMed ID: 18588904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of L-dopa on striatal acetylcholine release: effects of 6-hydroxydopamine.
    Jackson D; Abercrombie ED; Zigmond MJ
    J Pharmacol Exp Ther; 1993 Nov; 267(2):912-8. PubMed ID: 8246167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine receptor changes in response to prolonged treatment with L-dopa.
    Groppetti A; Flauto C; Parati E; Vescovi A; Rusconi L; Parenti M
    J Neural Transm Suppl; 1986; 22():33-45. PubMed ID: 2946813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
    Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
    Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
    Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output.
    Huang KX; Walters JR
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1434-43. PubMed ID: 7996456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
    St-Hilaire M; Landry E; Lévesque D; Rouillard C
    Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmented sensitivity of D1-dopamine receptors in lateral but not medial striatum after 6-hydroxydopamine-induced lesions in the neonatal rat.
    Simson PE; Johnson KB; Jurevics HA; Criswell HE; Napier TC; Duncan GE; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1992 Dec; 263(3):1454-63. PubMed ID: 1361576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissociation of the striatal D-2 dopamine receptor from adenylyl cyclase following 6-hydroxydopamine-induced denervation.
    Thomas KL; Rose S; Jenner P; Marsden CD
    Biochem Pharmacol; 1992 Jul; 44(1):73-82. PubMed ID: 1321630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.
    Calabresi P; Mercuri NB; Sancesario G; Bernardi G
    Brain; 1993 Apr; 116 ( Pt 2)():433-52. PubMed ID: 8096420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression of striatal synaptotagmin mRNA isoforms in hemiparkinsonian rats.
    Glavan G; Zivin M
    Neuroscience; 2005; 135(2):545-54. PubMed ID: 16111820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine.
    Meissner W; Ravenscroft P; Reese R; Harnack D; Morgenstern R; Kupsch A; Klitgaard H; Bioulac B; Gross CE; Bezard E; Boraud T
    Neurobiol Dis; 2006 Jun; 22(3):586-98. PubMed ID: 16531050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo studies of striatal dopamine release and metabolism following administration of L-dopa.
    Brannan T; Knott P; Kaufmann H; Yahr M
    Adv Neurol; 1990; 53():75-81. PubMed ID: 2173378
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 41.